Literature DB >> 26176030

Exacerbation of experimental autoimmune encephalomyelitis in mice deficient for DCIR, an inhibitory C-type lectin receptor.

Akimasa Seno, Takumi Maruhashi, Tomonori Kaifu, Rikio Yabe, Noriyuki Fujikado, Guangyu Ma, Tetsuro Ikarashi, Shigeru Kakuta, Yoichiro Iwakura.   

Abstract

Dendritic cell immunoreceptor (DCIR) is a C-type lectin receptor containing a carbohydrate recognition domain in its extracellular portion and an immunoreceptor tyrosine–based inhibitory motif, which transduces negative signals into cells, in its cytoplasmic portion. Previously, we showed that Dcir(–/–) mice spontaneously develop autoimmune diseases such as enthesitis and sialadenitis due to excess expansion of dendritic cells (DCs), suggesting that DCIR is critically important for the homeostasis of the immune system. In this report, we analyzed the role of DCIR in the development of experimental autoimmune encephalomyelitis (EAE), an autoimmune disease model for multiple sclerosis. We found that EAE was exacerbated in Dcir(–/–) mice associated with severe demyelination of the spinal cords. The number of infiltrated CD11c(+) DCs and CD4(+) T cells into spinal cords was increased in Dcir(–/–) mice. Recall proliferative response of lymph node cells was higher in Dcir(–/–) mice compared with wild-type mice. These observations suggest that DCIR is an important negative regulator of the immune system, and Dcir(–/–) mice should be useful for analyzing the roles of DCIR in an array of autoimmune diseases.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26176030      PMCID: PMC4427725          DOI: 10.1538/expanim.14-0079

Source DB:  PubMed          Journal:  Exp Anim        ISSN: 0007-5124


Introduction

Multiple sclerosis (MS) is an autoimmune inflammatory disease, in which myelin sheath surrounding the axon of a nerve cell is damaged, eventually causing neurological disorders, such as diplopia, bladder dysfunction, tremor and ataxia [7]. Experimental autoimmune encephalomyelitis (EAE) is the most popular animal model for MS, in which mice are immunized with myelin oligodendrocyte glycoprotein (MOG) as an autoreactive antigen. T cell infiltration into the spinal cords and pro-inflammatory cytokine production from the infiltrated cells are pathogenic for the development of EAE [14]. Both Th17 cells, which secrete IL-17, and Th1 cells, which produce Interferon(IFN)-γ, are detected in the affected spinal cords [39]. However, the pathogenic roles of IFN-γ are controversial. Peripheral administration of IFN-γ had no effect on the development of EAE, whereas intraventricular administration of IFN-γ alleviated or resolved the neurological deficits [3, 12, 43]. Thus, Th1 cells are dispensable, or rather beneficial, for the development of EAE. On the other hand, IL-17 is crucial for the development of encephalomyelitis; the development of EAE is significantly suppressed in Il17 mice [20]. IL-23 is an important cytokine which induces naive T cells to differentiate Th17 cells. Il23a mice do not develop EAE and IL-23 deficient T cells are less encephalitogenic than wild-type (WT) T cells [21, 41]. Granulocyte-macrophage colony-stimulating factor (GM-CSF), which stimulates dendritic cells (DCs) to secret IL-23, is also pathogenic in EAE [9]. Thus, encephalitogenic Th17 cells play crucial roles in the development of EAE. However, the mechanism how Th17 cell differentiation is controlled is largely unknown. DCs play an important role in the development of EAE as the antigen presenting cells to encephalitogenic T cells [15]. DCs present antigens from pathogens as well as from self to activate the acquired immune system. Furthermore, DCs sense pathogens by an array of innate immune receptors by recognizing pathogen associated molecular patterns such as glycoproteins, lipoproteins, and polysaccharides, which are exposed on the surface of pathogens, causing induction of cytokines and pathogen-specific T cell polarization [19, 31]. Innate immune receptor-mediated signalings are also important for the development of EAE [27]. C-type lectin receptors (CLRs) are one of such receptors [34] and regulate T cell responses in EAE [1, 15, 30, 45]. However, the regulatory mechanisms involving CLRs have not been elucidated yet. Dendritic cell immunoreceptor (DCIR; also named C-type lectin domain family 4 member a2 (Clec4a2) and C-type lectin super family 6 (Clecsf6)) is a CLR family protein, which contains carbohydrate recognition domain in the extracellular part and the immunoreceptor tyrosine-based inhibitory motif (ITIM) in the cytoplasmic region [2]. Because ITIM transduces negative signaling, DCIR is implicated in the suppression of cell function upon recognition of the ligands [11, 32, 33]. Previously, we found that Dcir is expressed in DCs and macrophages and the expression is greatly enhanced in the joints of rheumatoid arthritis models such as HTLV-I transgenic mice and IL-1 receptor antagonist deficient mice [10]. We showed that aged DCIR deficient (Dcir) mice spontaneously developed sialadenitis and enthesitis, associated with elevated serum autoantibodies and DC expansion [11]. Moreover, Dcir mice were more sensitive to collagen-induced arthritis, with elevated collagen-specific T cell responses, augmented antibody production against type II collagen, and expansion of DC population. We showed that DC expansion was caused by the deficiency of DCIR, because DCIR regulated the differentiation and proliferation of DCs by suppressing GM-CSF signaling through the inhibition of signal transducer and activator of transcription 5 phosphorylation [11]. These findings indicate that DCIR is an important regulator of the immune system by regulating the physiological levels of DCs in vivo and suggest that DCIR may be involved not only in the development of autoimmune arthritis but also in a wide range of autoimmune diseases. To examine this possibility, we have analyzed the effects of DCIR deficiency on the development of EAE using Dcir mice. We showed that the development of EAE was exacerbated in Dcir mice, with higher incidence, earlier onset, and severer symptoms than in WT mice. Histological analyses showed enhanced inflammation in the spinal cords of Dcir mice, where inflammatory score and demyelination of the nerves in the white matter were increased compared to those of WT mice. Infiltration of immune cells including CD4+ T cells and CD11c+ DCs into the spinal cord was greatly increased in Dcir mice at the late phase of EAE. Moreover, recall T cell proliferative response of Dcir mice against MOG35-55 peptide was higher than that of WT mice. These results clearly demonstrate that DCIR plays an important role in the development of EAE.

Materials and Methods

Mice

Dcir mice [11] were backcrossed to C57BL/6J (Japan SLC, Japan) over twelve generations. Age- and gender-matched WT C57BL/6J mice were purchased from Japan SLC. All mice were kept under specific pathogen–free conditions in environmentally controlled clean rooms at the Center for Experimental Medicine and Systems Biology, the Institute of Medical Science, the University of Tokyo, and Research Institute for Biomedical Sciences, Tokyo University of Science. All animal experiments were approved by the committees for animal experiments of both universities and conducted according to the institutional ethical guidelines for animal experiments and the safety guidelines for gene manipulation experiments.

Induction and evaluation of EAE

Progressive EAE was induced in WT and Dcir mice by subcutaneous immunization with 300 µg of MOG35-55 peptide (MEVGWYRSPFSRVVHLYRNGK) emulsified in 100 µl of incomplete Freund’s adjuvant (IFA) (Thermo Scientific, USA) and PBS (1:1) supplemented with 500 µg non-viable Mycobacterium Tuberculosis H37RA (Difco Laboratories Inc., USA) on day 0 and 7. MOG35-55 peptide was synthesized by solid-phase synthesizing methods and purified by HPLC by Prof. Ohmi (The Institute of Medical Science, The University of Tokyo, Japan). We judged the development of EAE by macroscopic evaluation. The clinical scores were graded as follows: 0, no disease; 1, limp tail; 2, hind limb weakness; 3, hind limb paralysis; 4, hind and fore limb paralysis and 5, moribund state. The mean clinical score was calculated by averaging the scores of all the mice in each group, including animals that seemingly did not develop EAE. Cumulative disease score is the sum of daily clinical scores of each individual mouse during the observation period and reported as an average within each group.

Histological analysis

At day 30 after immunization, mice were anesthetized with avertin (Sigma-Aldrich, USA) and perfused with PBS to rinse blood off from the spinal cords through the intracardiac route using a peristaltic pump set (ATTO, Japan) at a flow rate of 2 ml/min, followed by perfusion with 10% formalin neutral buffer solution, pH 7.4. Spinal cords, which were embedded in paraffin (Sakura Finetek, Japan) using Tissue-Tek (Sakura Finetek), were cross-sectioned at the between L3 and L5 level with 6 µm thickness, using a tissue microtome (BIOCUT microtome; Leica, Germany, or Sledge Microtome IVS-410; Sakura Finetek). Serial sections were stained with hematoxylin and eosin (H&E) (Sigma-Aldrich) or luxol fast blue (LFB) (Nacalai Tesque, Inc., Japan, or MUTO pure chemicals Co., LTD., Japan). Images were taken using a microscope (CKX41; OLYMPUS, Japan) with a camera (DP21; OLYMPUS). The inflammation conditions were evaluated using at least three tissue sections of the lumber spinal cord per mouse, followed by the instructions described below. We determined inflammation scores as follows: 0, no inflammation; 1, cellular infiltration only in the perivascular areas and meninges; 2, mild cellular infiltration (less than one third part of the white matter is infiltrated with inflammatory cells); 3, moderate cellular infiltration (more than one third part of the white matter is infiltrated with inflammatory cells); and 4, infiltration of inflammatory cells are observed in the whole white matter [25, 37]. We calculated demyelination as follows; pictures of the spinal cord were taken after LFB staining, the demyelinated area was determined with ImageJ software (National Institutes of Health, USA) and the ratio of demyelinated area/total area was calculated.

Measurement of anti-MOG35-55 antibody titers in serum

The titer of anti-MOG35-55 antibodies was detected by ELISA as described [28, 35], with the following modifications. Briefly, MOG35-55 peptide (3 μg per well) were coated on 96-well plates by incubating at 4°C overnight. After substantial washing with PBS, 30 μl of 100-fold diluted sera was incubated in duplicates for 1 h at room temperature. After washing, alkaline phosphatase-labeled goat anti-mouse Igs (ZYMED, USA) were reacted for 1 h at room temperature, followed by the addition of p-nitrophenyl phosphate substrate (Sigma-Aldrich). The titer of anti-MOG35-55 antibody was given as an absorbancy value at 415 nm.

Purification of lymphocytes in lymph nodes and infiltrated cells in the spinal cords

EAE-induced mice were anesthetized with avertin and perfused with PBS. Then, brachial and axillary lymph nodes (LNs) were collected and pooled. The entire spinal column was removed by gross dissection and spinal cords were ejected by a flush with a syringe attached in an 18-gauge needle. The LNs and spinal cords were incubated in 200 U/ml collagenase from Clostridium histolyticum (Sigma-Aldrich) in HBSS for 30 min at 37°C separately. Then, meshed lymphocytes were counted and analyzed. The cell suspension of dissociated spinal cord tissue in 30% Percoll (Sigma-Aldrich) was overlaid on a 70% Percoll in a 15 ml polypropylene tube and centrifuged at 2,200 rpm for 20 min at room temperature. Cells were collected from the interface between 30 and 70% Percoll.

Flow cytometric analysis

Whole spinal cord infiltrated cells or 2.0×105 lymphocytes were stained with 2 µg/ml monoclonal antibodies (mAbs) after Fcγ receptor blocking with 2.4G2 Ab. After cell surface staining, cells were fixed with 4% paraformaldehyde and permeabilized with 0.1% saponin, and then intracellular staining was performed. Anti-mouse CD11c (N418 or HL3), CD4 (RM4-5 or GK1.5), CD8 (53-6.7), CD40 (3/2, 3), CD80 (16-10A1), CD86 (GL-1), major histocompatibility complex class II (MHC class II) (M5/114.15.2), granulocyte-differentiation antigen-1 (Gr-1) (RB6-8C5), IFN-γ (XMG1.2) and IL-17A (TC11-18H10.1) were purchased from Biolegend (USA). Phcoerythrin (PE)-conjugated IL-17A (TC11-18H10) and biotin-conjugated anti-mouse OX40 ligand (OX40L) (RM134L) were purchased from BD Pharmingen (USA). PE/Cy7-conjugated streptavidin was purchased from BD Bioscience (USA). Stained cells were detected with a FACSCanto II Flow Cytometer (Becton, Dickinson and Company, USA) and analyzed with BD FACS Diva (Becton, Dickinson and Company) and FlowJo software (Tree Star, USA). Dead cells which stained by 7-Amino Actinomycin D (7-AAD) were excluded.

MOG35-55-specific T cell proliferation

WT and Dcir mice were subcutaneously immunized with 100 µg of MOG35-55 peptide emulsified in 100 µl of IFA (Thermo Scientific) and PBS (1:1) supplemented with 250 µg Mycobacterium Tuberculosis H37RA (Difco Laboratories Inc.) on day 0. They were intraperitoneally administrated with 200 μg of pertussis toxin (List Biological Labs, Inc., USA) in 100 μl PBS on day 0 and 2. Brachial and axillary LN cells were harvested at day 7 after immunization and cultured at 3 × 105 cells/well in 96-well culture plates with or without MOG35-55 for 3 days. [3H]TdR (0.25 µCi/ml) was incorporated for the last 6 hr and the radioactivity was measured with a MicroBeta (PerkinElmer, Inc., USA).

Statistical Analysis

We used the Student’s t-test for statistical evaluation of all results except for the EAE cumulative incidence and clinical score; they were evaluated by chi-square test and the Mann-Whitney U-test, respectively.

Results

DCIR–/– mice develop severer EAE compared to wild-type mice

To investigate the pathological role of DCIR in EAE, we monitored the development of clinical signs of EAE in Dcir mice after immunization with MOG35-55. Under our experimental conditions, two-third of WT mice developed EAE. By contrast, all the Dcir mice developed EAE (Fig. 1A, individual data are shown in Supplementary Fig. 1 and Supplementary Table 1) and the onset of the disease in Dcir mice was earlier than that of WT mice (Dcir; 16.4 ± 1.2, WT; 18.7 ± 2.7, *P < 0.05) (Fig. 1B). Also, the clinical score of Dcir mice (1.83 ± 0.46 at 23 days) was severer than that of WT mice (0.67 ± 0.48 at 23 days, *P < 0.05) (Fig. 1C), and the maximum score of the symptoms was higher (Dcir; 2.24 ± 0.33, WT; 1.11 ± 0.43, ***P < 0.005) (Fig. 1D). The cumulative disease score during day 10 to 30 was also higher in Dcir mice (Dcir; 18.0 ± 3.5, WT; 7.0 ± 4.2, ***P < 0.005) (Fig. 1E).
Fig. 1.

The development of EAE is exacerbated in Dcir–/– mice. WT and Dcir mice were immunized subcutaneously with MOG35-55 peptide emulsified in CFA, and the development of neurological symptoms was monitored for 30 days. (A) Cumulative incidence of EAE. (B) The average days of EAE onset among EAE developed mice in each group. (C) Mean EAE clinical score. (D) Mean maximum score in each mouse group. (E) Cumulative EAE scores in WT and Dcir mice over the course of the experiment. The data show combined results of three independent experiments with 5–16 mice for each group (individual data are shown in Supplementary Fig. 1 and Supplementary Table 1). Total number of mice examined was 27 for WT mice and 29 for Dcir mice. Data are expressed as the means + SEM for each group. *P<0.05 and ***P<0.005 vs. WT mouse score.

The development of EAE is exacerbated in Dcir–/– mice. WT and Dcir mice were immunized subcutaneously with MOG35-55 peptide emulsified in CFA, and the development of neurological symptoms was monitored for 30 days. (A) Cumulative incidence of EAE. (B) The average days of EAE onset among EAE developed mice in each group. (C) Mean EAE clinical score. (D) Mean maximum score in each mouse group. (E) Cumulative EAE scores in WT and Dcir mice over the course of the experiment. The data show combined results of three independent experiments with 5–16 mice for each group (individual data are shown in Supplementary Fig. 1 and Supplementary Table 1). Total number of mice examined was 27 for WT mice and 29 for Dcir mice. Data are expressed as the means + SEM for each group. *P<0.05 and ***P<0.005 vs. WT mouse score. Next, histopathology was examined in these mice. To examine the degrees of infiltration of immune cells in the spinal cords, a series of tissue sections of inflamed spinal cords at the lumber level from EAE-induced mice were stained with H&E (Fig. 2A). H&E staining showed that the infiltration of mononuclear cells and polymorphonuclear leukocytes into the spinal was observed at widespread area and inflammatory score was increased in Dcir mice compared with WT mice (Figs. 2A and B). Furthermore, LFB staining displayed that demyelination, which corresponds to weaker stain at anterior and lateral funiculus (arrowheads indicated the sites of demyelination) of the nerves in the white matter, was enhanced in Dcir mice compared with WT mice, (Fig. 2C and D). These demyelinated nerves were observed at the same site of inflammation (Figs. 2A and C). Furthermore, Gr-1+ cell infiltration into spinal cord tended to be increased in Dcir mice at day 28 after immunization (Supplementary Fig. 2). Therefore, the severe paralysis seen in Dcir mice is correlated with significant increases of inflammation and demyelination of the spinal cord. These results indicate that Dcir mice are highly susceptible to the development of EAE, suggesting that DCIR negatively regulates the development of EAE.
Fig. 2.

Histopathological examination of the EAE-developed spinal cords. (A) At day 30 after immunization, tissue sections of the spinal cords were stained with H&E. (B) Histological scores (inflammatory score) of the inflammatory lesions. (C) LFB-stained serial sections of (A). Their inflammatory scores are; WT = 1, and Dcir = 2. (D) Demyelination was calculated with the LFB-stained sections. Representative sections depicting inflammation and demyelination in the lumbar spinal cords of EAE mice. Arrows indicate infiltration of inflammatory cells in (A) and demyelination of the nerves in (C), and expanded pictures of anterior nerve-root are shown in lower panels. The percentage of demyelinated area was calculated as described in materials and methods. Quantitative results were obtained at least three sections per mouse from five mice in each group. The data are representative of two independent experiments with similar results. Their EAE clinical scores at day 30 were; WT = 0 or 1, Dcir = 1 to 3. We used the same or serial sections. Scale bar: 200 μm. Each graph represents as the mean + SD. *P<0.05 vs. WT mouse score.

Histopathological examination of the EAE-developed spinal cords. (A) At day 30 after immunization, tissue sections of the spinal cords were stained with H&E. (B) Histological scores (inflammatory score) of the inflammatory lesions. (C) LFB-stained serial sections of (A). Their inflammatory scores are; WT = 1, and Dcir = 2. (D) Demyelination was calculated with the LFB-stained sections. Representative sections depicting inflammation and demyelination in the lumbar spinal cords of EAE mice. Arrows indicate infiltration of inflammatory cells in (A) and demyelination of the nerves in (C), and expanded pictures of anterior nerve-root are shown in lower panels. The percentage of demyelinated area was calculated as described in materials and methods. Quantitative results were obtained at least three sections per mouse from five mice in each group. The data are representative of two independent experiments with similar results. Their EAE clinical scores at day 30 were; WT = 0 or 1, Dcir = 1 to 3. We used the same or serial sections. Scale bar: 200 μm. Each graph represents as the mean + SD. *P<0.05 vs. WT mouse score. As autoreactive antibodies were detected in sera of MS patients [46] and antibodies specific to MOG35-55 can amplify inflammation and demyelination in the central nervous system [24, 26], we measured the titer of MOG35-55-specific antibodies in the serum of immunized mice. The IgM-type anti-MOG35-55 antibodies did not significantly change in the serum. Antibody levels of the IgG1 and IgG2a subtype against MOG35-55 were increased after immunization with MOG35-55, but that of the IgG2b subtype was not increased (Fig. 3). However, no difference of antibody levels of these subtypes or total IgG was observed between Dcir mice and WT mice, suggesting that DCIR is dispensable for the production of autoantibodies.
Fig. 3.

MOG35-55-specific antibody levels in the serum of EAE-induced mice are similar between WT and Dcir–/– mice. Sera (WT, Dcir–/–: n=8 each) were collected at 20 days after immunization, and the levels of MOG35-55-specific antibodies were determined by ELISA. The data are expressed as means + SD, and are representative of two independent experiments. *P<0.05 vs. WT mouse score.

MOG35-55-specific antibody levels in the serum of EAE-induced mice are similar between WT and Dcir–/– mice. Sera (WT, Dcir–/–: n=8 each) were collected at 20 days after immunization, and the levels of MOG35-55-specific antibodies were determined by ELISA. The data are expressed as means + SD, and are representative of two independent experiments. *P<0.05 vs. WT mouse score.

Infiltration of CD11c+ cells and CD4+ T cells into the spinal cord is increased in Dcir–/– mice

Autoreactive T cells play an important role in the development of EAE. We found that infiltration of CD4+ and CD11c+ cells in the spinal cord was significantly increased in Dcir mice at 20 days after immunization, when the clinical score of Dcir mice was significantly higher than that of WT mice (Figs. 4A and B). CD4+ and CD11c+ cells in the draining LNs were also increased in Dcir mice (Figs. 4C and D). The proportion of CD4+ T cells was significantly increased in the LNs of Dcir mice at 7 days after immunization, whereas CD11c+ DCs were not (Figs. 5A and B). In spinal cord, the intensity of activation/maturation markers such as MHC class II, CD40, CD80, CD86, or OX40L on CD11c+ cells, however, was unchanged between WT and Dcir mice at day 20 (Fig. 6A). The intensity of these activation/maturation markers was also similar in LN cells (Fig. 6B). Moreover, the proportions of Th17 cells and Th1 cells, which are considered to be important for the development of EAE [14, 23, 44], in LNs were similar between WT and Dcir mice (Figs. 7A and B). Thus, these results demonstrate that cell infiltration into the spinal cord is greatly enhanced in Dcir mice, resulting in the exacerbation of EAE.
Fig. 4.

The numbers and proportions of infiltrated cells in the whole spinal cord (A, B) and in lymph nodes (LNs) (C, D) are increased in Dcir–/– mice. At 20 days after immunization, single cell suspensions were prepared from the spinal cords and LNs. Cells were analyzed by flow cytometry after staining with antibodies against indicated antigens. The data are expressed as means + SD, and are combined results of two independent experiments (A, B; WT, Dcir–/–: n=6 each, C, D; WT, Dcir–/–: n=9 each). *P<0.05, **P<0.01 and ***P<0.005 vs. WT mice.

Fig. 5.

CD4+ cells are increased in draining lymph nodes (LNs) of Dcir–/– mice after MOG35-55 and CFA immunization. At day 7 after immunization, single cell suspensions were prepared from the LNs. Cells were analyzed by flow cytometry after staining with antibodies against antigens. The cell numbers and proportion of CD11c+ and CD4+ cells were shown in (A) and (B) (WT, Dcir–/–: n=15 each). The data are expressed as means + SD, and are combined results of three independent experiments. **P<0.01 vs. WT mice.

Fig. 6.

The expression of activation markers on CD11c+ cells is similar between WT and Dcir–/– mice. (A, B) Single cell suspensions were prepared from spinal cords (A) and lymph nodes (LNs) (B) at day 20 after MOG35-55 and CFA immunization (WT: n=10, Dcir–/–: n=9). Cells were analyzed by flow cytometry after staining with antibodies against indicated antigens. The data are expressed as means + SD, and are combined results of two independent experiments.

Fig. 7.

Cytokine expression in LN CD4+ T cells is similar between WT and Dcir–/– mice. (A, B) Single cell suspensions were prepared from LNs at day 20 after MOG35-55 and CFA immunization, and after PMA/ionomycin stimulation, cells were stained with antibodies against indicated antigens and analyzed by flow cytometry (A). The proportion of IFN-γ+, IL-17+ and IFN-γ+ IL-17+ CD4+ cells are shown in (B) (WT, Dcir–/–: n=8 each). The data are expressed as means + SD, and are combined results of two independent experiments.

The numbers and proportions of infiltrated cells in the whole spinal cord (A, B) and in lymph nodes (LNs) (C, D) are increased in Dcir–/– mice. At 20 days after immunization, single cell suspensions were prepared from the spinal cords and LNs. Cells were analyzed by flow cytometry after staining with antibodies against indicated antigens. The data are expressed as means + SD, and are combined results of two independent experiments (A, B; WT, Dcir–/–: n=6 each, C, D; WT, Dcir–/–: n=9 each). *P<0.05, **P<0.01 and ***P<0.005 vs. WT mice. CD4+ cells are increased in draining lymph nodes (LNs) of Dcir–/– mice after MOG35-55 and CFA immunization. At day 7 after immunization, single cell suspensions were prepared from the LNs. Cells were analyzed by flow cytometry after staining with antibodies against antigens. The cell numbers and proportion of CD11c+ and CD4+ cells were shown in (A) and (B) (WT, Dcir–/–: n=15 each). The data are expressed as means + SD, and are combined results of three independent experiments. **P<0.01 vs. WT mice. The expression of activation markers on CD11c+ cells is similar between WT and Dcir–/– mice. (A, B) Single cell suspensions were prepared from spinal cords (A) and lymph nodes (LNs) (B) at day 20 after MOG35-55 and CFA immunization (WT: n=10, Dcir–/–: n=9). Cells were analyzed by flow cytometry after staining with antibodies against indicated antigens. The data are expressed as means + SD, and are combined results of two independent experiments. Cytokine expression in LN CD4+ T cells is similar between WT and Dcir–/– mice. (A, B) Single cell suspensions were prepared from LNs at day 20 after MOG35-55 and CFA immunization, and after PMA/ionomycin stimulation, cells were stained with antibodies against indicated antigens and analyzed by flow cytometry (A). The proportion of IFN-γ+, IL-17+ and IFN-γ+ IL-17+ CD4+ cells are shown in (B) (WT, Dcir–/–: n=8 each). The data are expressed as means + SD, and are combined results of two independent experiments.

MOG35-55-specific lymphocyte proliferative response is enhanced in Dcir–/– mice

We next examined the proliferative response to MOG35-55 of lymphocytes from mice immunized with MOG35-55 and CFA plus pertussis toxin. Lymphocytes were collected from the draining LNs of WT and Dcir mice at 7 days after immunization. We found that the proliferation of Dcir lymphocytes was significantly enhanced than that of WT mice (Fig. 8). These results suggest that immunization efficiency is enhanced in Dcir mice.
Fig. 8.

T cell recall proliferative response against MOG35-55 peptide is enhanced in lymphocytes from Dcir–/– mice. LN cells were harvested from mice (n=6) at day 7 after immunization with MOG35-55, CFA, and pertussis toxin. Pooled cells were incubated in the presence or absence of MOG35-55 peptide for 3 days. [3H]TdR was incorporated over the last 6 hr, and the incorporation of [3H] into acid insoluble fraction was measured. Data are presented as means + SD, and are representative of two independent experiments. *P<0.05 and **P<0.01 vs. WT mice.

T cell recall proliferative response against MOG35-55 peptide is enhanced in lymphocytes from Dcir–/– mice. LN cells were harvested from mice (n=6) at day 7 after immunization with MOG35-55, CFA, and pertussis toxin. Pooled cells were incubated in the presence or absence of MOG35-55 peptide for 3 days. [3H]TdR was incorporated over the last 6 hr, and the incorporation of [3H] into acid insoluble fraction was measured. Data are presented as means + SD, and are representative of two independent experiments. *P<0.05 and **P<0.01 vs. WT mice.

Discussion

In this report, we showed that the development of EAE was significantly exacerbated in Dcir mice. The EAE score was significantly increased in Dcir mice, indicating that DCIR is an important regulator of the disease. Because autoantibodies play an important role in the development of autoimmune diseases such as rheumatoid arthritis [4, 17, 22, 36] and MS [16, 26, 29], MOG35-55-specific Ig production was examined in EAE-induced mice. However, we found that serum levels of MOG35-55-specific antibodies of the IgM, IgG1, IgG2a, and IgG2b subclasses were similar in Dcir mice and WT mice. Consistent with these results, we previously reported that serum levels of MOG35-55-specific Ig are not correlated with the development of EAE [20]. Furthermore, it was reported that autoantibody levels are not always proportional to EAE disease scores [18]. These results suggest that antibody-mediated humoral immune responses are dispensable for the development of EAE. On the other hand, we found that infiltration of DCs and CD4+ T cells into the spinal cord was significantly increased in Dcir mice, suggesting CD4+ T cell-mediated cellular immune responses are important for the development of EAE. DCs play a central role in regulating the acquired immune system [6, 42]. Activation of T cells against pathogens and tolerance induction of autoreactive T cells are tightly controlled by DCs. If this regulation fails, T cells incorrectly recognize self-antigens and develop autoimmunity. DCs are also one of key modulators of encephalitogenic T cells, as shown in human MS and murine EAE [6]. During the development of EAE, peripheral DCs are sufficient to present antigens to prime myelin-reactive T cells and initiate disease development [8, 15, 30]. We found that recall T cell proliferative response against MOG35-55 antigen was significantly augmented in T cells from Dcir mice, indicating that T cell priming is facilitated in Dcir mice. It was reported that pathogenic Th17 cells, which is important for the development of EAE, secrete GM-CSF, promoting accumulation of inflammatory macrophages into the CNS and activating DCs to induce IL-23 production. The secreted IL-23 in turn promotes Th17 cell differentiation, forming an amplification loop [5, 9]. We have previously shown that DCIR negatively regulates DC differentiation and proliferation by suppressing GM-CSF receptor signaling through the ITIM in this molecule [11]. Indeed, we found that the CD11c+ DC number was significantly increased in the inflamed spinal cord and LNs of Dcir mice. However, the expression of CD80, CD86 and MHC class II molecules on CD11c+ DCs was normal in Dcir mice, indicating that DCIR may not be involved in the maturation/activation of DCs. The expression of CD40 and OX40L, other activation markers, was also normal in these mice. Although we could not detect preferential expansion of Th17 cells in LNs (Fig. 7) nor increased production of IL-17 and IL-23 (data not shown), total CD4+ cells in the spinal cord and LNs were significantly increased in these Dcir mice. Accordingly, total Th17 cell number in the spinal cord and draining LNs should be increased in these mice to promote inflammation after immunization with MOG peptides (Fig. 4). Therefore, these observations suggest that excess antigen presentation due to increased DC number which is caused by the hyper-responsiveness of DCs to GM-CSF, but not activation status of DCs, is responsible for the enhanced differentiation/proliferation of T cells after immunization with MOG35-55. MS is an inflammatory disease in the central nervous system associated with demyelination of nerve cells, axonal loss/damage and gliosis. There is several MS types in terms of the clinical course; relapsing-remitting MS, secondary progressive MS (the late stage of relapsing-remitting MS) and primary progressive MS. Its clinical signs differ depending on the inflammation sites; the most common manifestations are somatosensory, pyramidal-motor and visual manifestations. Similar neuroinflammatory disorder called EAE is induced experimentally in animals by injecting myelin antigens. Symptomes of EAE differ depending on the experimental conditions including the animals and the induction methods. C57BL/6 mice immunized with MOG35-55 in CFA with a booster injection at 7 days after the first immunization show the symptoms resembling secondary progressive MS with a gradual neurological deterioration. EAE clinical signs are scored as paralysis of their tail and extremities [13, 38, 40]. Tissue injury in both MS and EAE could be seen in the white matter of CNS [13, 14]. EAE was induced in Dcir mice similarly as in C57BL/6 WT mice, but infiltration of leukocytes into the spinal cord was much enhanced and the histopathology was severer than that of WT, although the infiltrating cell population was similar to that of WT. Taken together, these observations clearly show that DCIR is important not only in the development of autoimmune arthritis but also in the development of EAE, suggesting that DC regulation mediated by DCIR is generally important for the development of autoimmune diseases. Thus, targeting DCIR to harness DC differentiation/proliferation is one of important strategies to prevent or limit autoimmune diseases, and small compounds which can activate DCIR or agonistic antibodies should be good candidates to treat autoimmune diseases. Moreover, because DCIR also regulates other signals, such as toll-like receptor signals [32, 33], and is expressed in cells other than DCs, such as macrophages [2], targeting DCIR may also be useful to control broader range of diseases including infectious diseases. Our studies also indicate that Dcir mice are useful for the studies of autoimmune diseases, because autoimmunity is easily induced in these mice. Clearly, further investigation is needed to elucidate the functions and roles of DCIR under healthy conditions and in diseases.
  46 in total

1.  CNS myeloid DCs presenting endogenous myelin peptides 'preferentially' polarize CD4+ T(H)-17 cells in relapsing EAE.

Authors:  Samantha L Bailey; Bettina Schreiner; Eileen J McMahon; Stephen D Miller
Journal:  Nat Immunol       Date:  2007-01-07       Impact factor: 25.606

Review 2.  Recognition of microorganisms and activation of the immune response.

Authors:  Ruslan Medzhitov
Journal:  Nature       Date:  2007-10-18       Impact factor: 49.962

3.  Active induction of experimental allergic encephalomyelitis.

Authors:  Ingunn M Stromnes; Joan M Goverman
Journal:  Nat Protoc       Date:  2006       Impact factor: 13.491

4.  Differential regulation of central nervous system autoimmunity by T(H)1 and T(H)17 cells.

Authors:  Ingunn M Stromnes; Lauren M Cerretti; Denny Liggitt; Robert A Harris; Joan M Goverman
Journal:  Nat Med       Date:  2008-02-17       Impact factor: 53.440

Review 5.  Dendritic cell subsets in health and disease.

Authors:  Hideki Ueno; Eynav Klechevsky; Rimpei Morita; Caroline Aspord; Tinghua Cao; Toshimichi Matsui; Tiziana Di Pucchio; John Connolly; Joseph W Fay; Virginia Pascual; A Karolina Palucka; Jacques Banchereau
Journal:  Immunol Rev       Date:  2007-10       Impact factor: 12.988

6.  IL-23 is critical in the induction but not in the effector phase of experimental autoimmune encephalomyelitis.

Authors:  Paresh Thakker; Michael W Leach; Wen Kuang; Stephen E Benoit; John P Leonard; Suzana Marusic
Journal:  J Immunol       Date:  2007-02-15       Impact factor: 5.422

7.  Identification of a pathogenic antibody response to native myelin oligodendrocyte glycoprotein in multiple sclerosis.

Authors:  Dun Zhou; Rajneesh Srivastava; Stefan Nessler; Verena Grummel; Norbert Sommer; Wolfgang Brück; Hans-Peter Hartung; Christine Stadelmann; Bernhard Hemmer
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-01       Impact factor: 11.205

8.  Dcir deficiency causes development of autoimmune diseases in mice due to excess expansion of dendritic cells.

Authors:  Noriyuki Fujikado; Shinobu Saijo; Tomo Yonezawa; Kazusuke Shimamori; Akina Ishii; Sho Sugai; Hayato Kotaki; Katsuko Sudo; Masato Nose; Yoichiro Iwakura
Journal:  Nat Med       Date:  2008-01-20       Impact factor: 53.440

9.  B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.

Authors:  Stephen L Hauser; Emmanuelle Waubant; Douglas L Arnold; Timothy Vollmer; Jack Antel; Robert J Fox; Amit Bar-Or; Michael Panzara; Neena Sarkar; Sunil Agarwal; Annette Langer-Gould; Craig H Smith
Journal:  N Engl J Med       Date:  2008-02-14       Impact factor: 91.245

10.  Identification of arthritis-related gene clusters by microarray analysis of two independent mouse models for rheumatoid arthritis.

Authors:  Noriyuki Fujikado; Shinobu Saijo; Yoichiro Iwakura
Journal:  Arthritis Res Ther       Date:  2006       Impact factor: 5.156

View more
  11 in total

1.  C-type lectin receptor DCIR modulates immunity to tuberculosis by sustaining type I interferon signaling in dendritic cells.

Authors:  Anthony Troegeler; Ingrid Mercier; Céline Cougoule; Danilo Pietretti; André Colom; Carine Duval; Thien-Phong Vu Manh; Florence Capilla; Renaud Poincloux; Karine Pingris; Jérôme Nigou; Jörg Rademann; Marc Dalod; Frank A W Verreck; Talal Al Saati; Geanncarlo Lugo-Villarino; Bernd Lepenies; Denis Hudrisier; Olivier Neyrolles
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-09       Impact factor: 11.205

2.  Therapeutic Potential of Combined Therapy of Vitamin A and Vitamin C in the Experimental Autoimmune Encephalomyelitis (EAE) in Lewis Rats.

Authors:  Mojdeh Navidhamidi; Atena Nazari; Samaneh Dehghan; Anahita Ebrahimpour; Reza Nasrnezhad; Fereshteh Pourabdolhossein
Journal:  Mol Neurobiol       Date:  2022-01-24       Impact factor: 5.590

3.  Dectin-1 limits autoimmune neuroinflammation and promotes myeloid cell-astrocyte crosstalk via Card9-independent expression of Oncostatin M.

Authors:  M Elizabeth Deerhake; Keiko Danzaki; Makoto Inoue; Emre D Cardakli; Toshiaki Nonaka; Nupur Aggarwal; William E Barclay; Ru-Rong Ji; Mari L Shinohara
Journal:  Immunity       Date:  2021-02-12       Impact factor: 43.474

Review 4.  C-Type Lectin-Like Receptors As Emerging Orchestrators of Sterile Inflammation Represent Potential Therapeutic Targets.

Authors:  Elise Chiffoleau
Journal:  Front Immunol       Date:  2018-02-15       Impact factor: 7.561

5.  C-type lectin receptor CLEC4A2 promotes tissue adaptation of macrophages and protects against atherosclerosis.

Authors:  Michael E Goddard; Jennifer E Cole; Inhye Park; Natacha Zanin; Leo-Pekka Lyytikäinen; Terho Lehtimäki; Evangelos Andreakos; Marc Feldmann; Irina Udalova; Ignat Drozdov; Claudia Monaco
Journal:  Nat Commun       Date:  2022-01-11       Impact factor: 17.694

6.  C-type lectin receptor DCIR contributes to hippocampal injury in acute neurotropic virus infection.

Authors:  Melanie Stoff; Tim Ebbecke; Malgorzata Ciurkiewicz; Suvarin Pavasutthipaisit; Sabine Mayer-Lambertz; Theresa Störk; Kevin D Pavelko; Wolfgang Baumgärtner; Klaus Jung; Bernd Lepenies; Andreas Beineke
Journal:  Sci Rep       Date:  2021-12-10       Impact factor: 4.379

7.  Effects of cigarette smoke exposure on a mouse model of multiple sclerosis.

Authors:  Jenny Ho; Kyoko Koshibu; Wenhao Xia; Karsta Luettich; Athanasios Kondylis; Llenalia Garcia; Blaine Phillips; Manuel Peitsch; Julia Hoeng
Journal:  Toxicol Rep       Date:  2022-03-29

8.  The CTRP3-AdipoR2 Axis Regulates the Development of Experimental Autoimmune Encephalomyelitis by Suppressing Th17 Cell Differentiation.

Authors:  Masanori A Murayama; Hsi-Hua Chi; Mako Matsuoka; Takahiro Ono; Yoichiro Iwakura
Journal:  Front Immunol       Date:  2021-12-02       Impact factor: 7.561

9.  DCIR and its ligand asialo-biantennary N-glycan regulate DC function and osteoclastogenesis.

Authors:  Tomonori Kaifu; Rikio Yabe; Takumi Maruhashi; Soo-Hyun Chung; Hiroaki Tateno; Noriyuki Fujikado; Jun Hirabayashi; Yoichiro Iwakura
Journal:  J Exp Med       Date:  2021-11-24       Impact factor: 17.579

10.  Piperine Improves Experimental Autoimmune Encephalomyelitis (EAE) in Lewis Rats Through its Neuroprotective, Anti-inflammatory, and Antioxidant Effects.

Authors:  Reza Nasrnezhad; Sohrab Halalkhor; Farzin Sadeghi; Fereshteh Pourabdolhossein
Journal:  Mol Neurobiol       Date:  2021-08-02       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.